Impact of in‐hospital bleeding according to the bleeding academic research consortium classification on the long‐term adverse outcomes in patients undergoing percutaneous coronary intervention

The aim of this study was to assess the impact of bleeding after percutaneous coronary intervention (PCI) with drug‐eluting stents on long‐term clinical events according to the newly proposed Bleeding Academic Research Consortium (BARC) classification.

[1]  M. Jeong,et al.  Outcomes After Unrestricted Use of Everolimus-Eluting and Sirolimus-Eluting Stents in Routine Clinical Practice: A Multicenter, Prospective Cohort Study , 2012, Circulation. Cardiovascular Interventions.

[2]  M. Hadamitzky,et al.  Validation of the Bleeding Academic Research Consortium Definition of Bleeding in Patients With Coronary Artery Disease Undergoing Percutaneous Coronary Intervention , 2012, Circulation.

[3]  E. Antman,et al.  Predictors of Bleeding and Time Dependence of Association of Bleeding With Mortality: Insights From the Trial to Assess Improvement in Therapeutic Outcomes by Optimizing Platelet Inhibition With Prasugrel—Thrombolysis in Myocardial Infarction 38 (TRITON-TIMI 38) , 2011, Circulation.

[4]  Marco Valgimigli,et al.  Standardized Bleeding Definitions for Cardiovascular Clinical Trials: A Consensus Report From the Bleeding Academic Research Consortium , 2011, Circulation.

[5]  S. Pocock,et al.  Impact of bleeding on mortality after percutaneous coronary intervention results from a patient-level pooled analysis of the REPLACE-2 (randomized evaluation of PCI linking angiomax to reduced clinical events), ACUITY (acute catheterization and urgent intervention triage strategy), and HORIZONS-AMI , 2011, JACC. Cardiovascular interventions.

[6]  Seung‐Jung Park,et al.  Impact of bleeding on subsequent early and late mortality after drug-eluting stent implantation. , 2011, JACC. Cardiovascular interventions.

[7]  Sunil V. Rao,et al.  Antiplatelet Therapy Use After Discharge Among Acute Myocardial Infarction Patients With In-Hospital Bleeding , 2008, Circulation.

[8]  S. Yusuf,et al.  Improving clinical outcomes by reducing bleeding in patients with non-ST-elevation acute coronary syndromes. , 2008, European heart journal.

[9]  J. Gore,et al.  Does Comorbidity Account for the Excess Mortality in Patients With Major Bleeding in Acute Myocardial Infarction? , 2007, Circulation.

[10]  P. Serruys,et al.  Clinical End Points in Coronary Stent Trials: A Case for Standardized Definitions , 2007, Circulation.

[11]  S. Yusuf,et al.  Adverse Impact of Bleeding on Prognosis in Patients With Acute Coronary Syndromes , 2006, Circulation.

[12]  R. Califf,et al.  Impact of bleeding severity on clinical outcomes among patients with acute coronary syndromes. , 2005, The American journal of cardiology.

[13]  I. Iakovou,et al.  Incidence, predictors, and outcome of thrombosis after successful implantation of drug-eluting stents. , 2005, JAMA.

[14]  P. Cerboni,et al.  Coronary syndromes following aspirin withdrawal: a special risk for late stent thrombosis. , 2005, Journal of the American College of Cardiology.

[15]  Sunil V. Rao,et al.  Relationship of blood transfusion and clinical outcomes in patients with acute coronary syndromes. , 2004, JAMA.

[16]  D. Mangano.  Aspirin and mortality from coronary bypass surgery. , 2002, The New England journal of medicine.

[17]  R. Ferrari,et al.  The neuroendocrine and sympathetic nervous system in congestive heart failure. , 1998, European heart journal.

[18]  Dwight E. Peake,et al.  Thrombolysis in myocardial infarction (TIMI) trial: Phase I. A comparison between intravenous tissue plasminogen activator and intravenous streptokinase , 1988 .

[19]  R Roberts,et al.  Thrombolysis in Myocardial Infarction (TIMI) Trial, Phase I: A comparison between intravenous tissue plasminogen activator and intravenous streptokinase. Clinical findings through hospital discharge. , 1987, Circulation.

[20]  Harold T. Dodge,et al.  Thrombolysis inMyocardial Infarction (TIMI) Trial, Phase I:acomparison between intravenous tissue plasminogen activator andintravenous streptokinase* , 1987 .